These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15988670)

  • 1. [Epidemiology and costs of diabetes mellitus in Germany].
    Hauner H
    Dtsch Med Wochenschr; 2005 Jul; 130 Suppl 2():S64-5. PubMed ID: 15988670
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diabetes care in sub-Saharan Africa].
    Labie D
    Med Sci (Paris); 2007 Mar; 23(3):320-2. PubMed ID: 17349296
    [No Abstract]   [Full Text] [Related]  

  • 3. Diabetes costs rise, but so does adherence.
    Manag Care; 2005 Apr; 14(4):54. PubMed ID: 15898213
    [No Abstract]   [Full Text] [Related]  

  • 4. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA; Redaelli M; Wendland G; Civello D; Lauterbach KW
    Diabet Med; 2006 Mar; 23(3):299-305. PubMed ID: 16492214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diabetes mellitus--high costs, good prospects].
    Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):83. PubMed ID: 16550879
    [No Abstract]   [Full Text] [Related]  

  • 7. Epidemiology and costs of diabetes treated with insulin in France.
    Detournay B; Raccah D; Cadilhac M; Eschwège E
    Diabetes Metab; 2005 Jun; 31(3 Pt 2):3-18. PubMed ID: 16142041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Insulin analogues--which dimension should be discussed?].
    Verspohl EJ
    Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
    [No Abstract]   [Full Text] [Related]  

  • 9. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004.
    Patel H; Srishanmuganathan J; Car J; Majeed A
    J Public Health (Oxf); 2007 Mar; 29(1):48-52. PubMed ID: 17124257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Epidemiology of diabetes in metropolitan France].
    Ricordeau P; Weill A; Vallier N; Bourrel R; Fender P; Allemand H
    Diabetes Metab; 2000 Sep; 26 Suppl 6():11-24. PubMed ID: 11011236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir.
    Freemantle N; Stella P; Munro V
    Curr Med Res Opin; 2007 Aug; 23(8):1761-2; author reply 1762-4. PubMed ID: 17588305
    [No Abstract]   [Full Text] [Related]  

  • 14. The future of diabetes technologies and therapeutics.
    Jones M; Harrison JM
    Diabetes Technol Ther; 2002; 4(3):351-9. PubMed ID: 12165175
    [No Abstract]   [Full Text] [Related]  

  • 15. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 16. [Reduced neuropathic risk via enhanced glucose control?].
    Ziegler D
    Dtsch Med Wochenschr; 2013 Mar; 138(11):513. PubMed ID: 23463469
    [No Abstract]   [Full Text] [Related]  

  • 17. Rising Costs of Drug/Insulin Treatment for Diabetes: A Perspective from India.
    Misra A; Mukherjee R; Luthra A; Singh P
    Diabetes Technol Ther; 2017 Dec; 19(12):693-698. PubMed ID: 29090974
    [No Abstract]   [Full Text] [Related]  

  • 18. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 19. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes in Africa. Challenges to health care for diabetes in Africa.
    Whiting DR; Hayes L; Unwin NC
    J Cardiovasc Risk; 2003 Apr; 10(2):103-10. PubMed ID: 12668907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.